Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

By L. Bjerre Knudsen, L. Madsen, Søren Andersen, K. Almholt, A. S. de Boer, D. J. Drucker, C. Gotfredsen, F. L. Egerod, A. C. Hegelund, H. Jacobsen and 9 more. Endocrinology, 2010

641 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/64d7bf57a826e8b5132d73af6d20c75da4c1a7e2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. D. J. Drucker
2. J. Meier
3. M. Nauck
4. L. Knudsen
5. Jonathan E. Campbell
6. F. Reimann
7. F. Gribble
8. Ralph DeFronzo

In Molecular Biology

1. D. J. Drucker
2. M. Nauck
3. J. Meier
4. Jonathan E. Campbell

In Surgery

1. D. J. Drucker
2. J. Meier
3. M. Nauck
4. Jonathan E. Campbell
5. L. Knudsen
6. F. Reimann
7. F. Gribble
8. Ralph DeFronzo

Citations in the corpus

• Pharmacology, physiology, and mechanisms of incretin hormone action. (2013, background): “However C cell GLP-1R density and proliferation in response to GLP-1R agonists is highly species specific, and GLP-1R agonists do not promote C cell proliferation or increases in calcitonin levels in primate studies after 87 weeks of exposure (Bjerre Knudsen et al., 2010).”
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “Nevertheless, thyroid C cells express GLP-1 receptors [107], and subjects at risk of (rare) medullary thyroid cancer (e.”
• Glucagon-like peptide 1 (GLP-1) (2019, background): “thyroid [855,856], and involvement of calcitonin in GLP-1-mediated osteoclast activation has been suspected [854].”
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. (2014, methodology): “In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
• Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018, background): “In contrast, the density of GLP-1Rs on monkey and human thyroid cells is extremely low, and sustained GLP-1R agonism does not cause calcitonin secretion, C cell hyperplasia, or MTC in non-human primates (Bjerre Knudsen et al., 2010; Vahle et al., 2015).”